As debate grows over psychedelic medicine, thousands of veterans hope President Trump’s new order could speed access to promising treatments for severe mental illness.

Story Snapshot

• Trump’s April 18 executive order tells the Food and Drug Administration (FDA) to fast-track certain psychedelic drugs for serious mental illness, with veterans at the front of the line.
• The order moves at least $50 million inside the Department of Health and Human Services (HHS) to help states run psychedelic treatment and research programs.
• The Food and Drug Administration is issuing special “national priority vouchers” for drugs like psilocybin and similar compounds, cutting review times from months to weeks.
• The Department of Veterans Affairs (VA) is launching a new government-run trial of MDMA‑assisted therapy for post‑traumatic stress and alcohol use disorder in 80 veterans.

Trump’s Order: Fast-Tracking Psychedelics For Mental Illness

On April 18, 2026, President Donald Trump signed an order called “Accelerating Medical Treatments for Serious Mental Illness.” It tells federal health agencies to speed up research, review, and possible approval of certain psychedelic drugs for conditions like major depression and substance use disorder. The order says veterans should be a key focus, reflecting long‑standing anger that many former service members wait months or years for effective mental health care. This move comes after years of frustration on both left and right with a system that talks about “supporting veterans” but rarely delivers real change.

The order gives the Food and Drug Administration direct marching orders. It says the agency must prioritize drugs that already have a “Breakthrough Therapy” label and push them through a new National Priority Voucher Program. These vouchers can greatly shrink the review window, sometimes from six to ten months down to one or two. Supporters argue this is a science‑based way to get promising treatments to patients who are out of options, instead of leaving decisions to slow committees and risk‑avoiding bureaucrats who never personally face post‑traumatic stress disorder or addiction.

Money, States, And “Right To Try” Pathways

Alongside faster reviews, the order shifts real money. It directs the Secretary of Health and Human Services to move at least $50 million from existing funds into projects run through the Advanced Research Projects Agency for Health. That money will match investments by states that are already building programs around psychedelic drugs for serious mental illness. The goal is to create a national network that ties together state clinics, federal regulators, and the Department of Veterans Affairs so they share data instead of hiding it in separate silos.

The order also leans on the federal “Right to Try Act,” which lets some very sick patients access drugs that are still under review. It instructs the Food and Drug Administration and the Drug Enforcement Administration to set up a pathway for eligible patients, including veterans, to use investigational psychedelic drugs such as ibogaine once basic safety bars are met. Backers say this helps people who cannot wait years for perfect data. Critics worry it opens a side door around standard safety rules, especially for compounds like ibogaine that carry known heart risks and have almost no United States clinical trial history.

Veterans’ Groups Applaud, Safety Experts Pump The Brakes

Veterans’ organizations have not stayed quiet. The Veterans of Foreign Wars publicly praised the order, calling it a possible “transformative” step for former service members battling post‑traumatic stress disorder, depression, and other severe mental illnesses when standard pills and talk therapy have failed. They highlight that the order does not instantly legalize psychedelics but does clear a faster path from research to tightly controlled medical use. For many veterans, this feels like Washington finally listening to years of testimony that “business as usual” mental health care is not working.

At the same time, doctors and researchers point to recent history as a warning light. In August 2024, the Food and Drug Administration rejected an application for MDMA‑assisted therapy for post‑traumatic stress disorder after advisers found serious flaws in the trial designs and raised alarms about safety, including heart problems. That decision showed that even strong political pressure and emotional stories do not erase the agency’s duty to prove a drug is both safe and effective. Experts now stress that rushing review cannot mean skipping careful trial design, independent oversight, and long‑term follow‑up, especially for drugs that alter mood and perception.

New VA Trials, Old Trust Problems With Washington

The Department of Veterans Affairs is trying to directly answer some of these concerns. Following the order, the VA registered a randomized controlled trial of MDMA‑assisted therapy for post‑traumatic stress disorder and alcohol use disorder involving 80 veterans. Because this trial is run by the government itself, with stricter oversight and clearer protocols, many researchers see it as a chance to fix design issues that doomed earlier private studies. If the results are strong and transparent, they could support both faster approvals and stricter guardrails so veterans are protected, not used as test subjects.

Why did they lead this Executive Order with Ibogaine instead of mushrooms?

Almost no one has heard of Ibogaine — and that's precisely the point. It sounds like a pharmaceutical already, not some obscure African shrub. It arrives without baggage.

Mushrooms, on the other hand,…

— Jon Rob (@homogalactic) June 29, 2026

Still, many veterans and civilians share a deeper worry that goes beyond psychedelics. They see an executive order that promises “breakthrough” care while the larger system still feels rigged for elites, lobbyists, and corporate interests. Media stories have already noted stock jumps for companies tied to the voucher program and questioned whether industry pressure helped shape the policy. At the same time, families scarred by suicide and addiction look at decades of failure and ask a blunt question: if Washington can move this fast under political pressure, why was it so slow when ordinary people begged for help? That tension—between hope for new treatments and anger at a government that seems to wake up only when power or profit is on the line—is why this order is drawing such fierce debate across the political spectrum.

Sources:

redstate.com, usmedicine.com, youtube.com, npr.org, facebook.com, fda.gov, whitehouse.gov, jamanetwork.com, psychedelic.support, pmc.ncbi.nlm.nih.gov, pbs.org, petrieflom.law.harvard.edu